Protocol
10-007
Full Title
A Randomized Phase III Trial of Paclitaxel Plus Carboplatin Versus Ifosfamide Plus Paclitaxel in Chemotherapy-Naive Patients with Newly Diagnosed Stage I-IV Persistent or Recurrent Carcinosarcoma (Mixed Mesodermal Tumors) of the Uterus, Fallopian Tube, Peritoneum or Ovary (GOG 261)
Purpose
The purpose of this Gynecologic Oncology Group study is to compare the effectiveness of two different drug regimens for patients newly diagnosed with uterine carcinosarcoma. Patients will be randomly assigned to receive either carboplatin/paclitaxel or ifosfamide/paclitaxel.
All of these drugs have been shown to be active against uterine carcinosarcoma. Doctors and researchers believe that the combination of carboplatin and paclitaxel may work just as well as ifosfamide and paclitaxel, yet with fewer side effects.
Investigator
Eligibility
To be eligible for this study, patients must meet several criteria, including but not limited to the following:
- Patients must have newly diagnosed stage I, II, III, or IV uterine carcinosarcoma that has not yet been treated with chemotherapy.
- Patients must have recovered from any prior radiation therapy or surgery.
- Patients must be age 18 or older.
For more information and to inquire about eligibility for this study, please contact Dr. Martee L. Hensley at 212-639-6902.
Disease(s)
Endometrial and other Uterine Cancers: Uterine Cancer
Sarcomas
Sarcomas: Soft Tissue Sarcoma
Locations
Related Diseases
